Description
Lung Cancer Therapy Annual 7 (7th Ed.)
Coordinator: Stahel Rolf A.
Language: English
Subjects for Lung Cancer Therapy Annual 7:
Keywords
Gefi Tinib; EGFR Mutation; Epidemiology of lung cancer; Activate EGFR Mutation; Prevention; early detection and screening; EGFR TKIS; Oncogenic driver mutations; Advanced NSCLC; Mesothelioma; EGFR T790; Advances in surgery of lung cancer; Mediastinal Lymph Node; Wild Type EGFR; Advanced NSCLC Patient; Median PFS; Limited Stage SCLC; NSCLC Patient; Median Os; Lung Cancer; Thymic Malignancies; TC; SABR; Alk Rearrangement; Mage A3 Vaccine; EML4 Alk Translocation; Stage Ii; Driver Mutations; KRAS Mutation; Concurrent Chemo Radiation
Support: Print on demand
Description
/li>Contents
/li>Readership
/li>Biography
/li>
Highly Commended, BMA Medical Book Awards 2013
Oncology research and practice in lung cancer continues to develop rapidly. This latest edition of an acclaimed reference briefs the oncology community with a review of the recent literature, emphasizing the most significant therapeutic advances. The expert contributions ofLung Cancer Therapy Annual7 offer an update of the impact that this information will have on the day-to-day management of the lung cancer patient.
New to the seventh edition are four new chapters on the treatment of non-small cell lung cancer (NSCLC) and a new chapter on thymoma. Additional topics include:
- Oncogenic driver mutations
- First line therapy of advanced non-small cell lung cancer without activating EGFR mutation
- Second line therapy of non-small cell lung cancer
- Adjunct and neoadjunct therapy of non-small cell lung cancer
- Advances in surgery of lung cancer; advances in radiotherapy of lung cancer
- Mesothelioma
- Thymic tumors
1. Epidemiology
2. Prevention, early detection, and screening
3. Staging
4. Histopathology and molecular pathology
5. Oncogenic driver mutations
6. First line therapy of advanced non-small cell lung cancer without activating EGFR mutation
7. First line therapy of advanced non-small cell lung cancer with activating EGFR mutation
8. Second line therapy of non-small cell lung cancer
9. Adjuvant and neoadjuvant therapy of non-small cell lung cancer
10. Advances in surgery of lung cancer
11. Advances in radiotherapy of lung cancer
12. Small cell lung cancer
13. Mesothelioma
14. Thymoma
Rolf A. Stahel, M.D. is head of the Center for Lung and Thoracic Oncology and Senior Staff Physician at the Clinic of Oncology, University Hospital of Zürich as well as Titular Professor of Medicine at the University of Zürich, Switzerland. He is certified in Internal Medicine and Medical Oncology by both the American and Swiss Board. His major interest is thoracic oncology, including multidisciplinary treatment approaches, translational research, and targeted therapy.
